Benfotiamine at 600mg: Why the Lipid-Soluble Thiamine Analogue Clears the Gut-Transporter Ceiling That Caps Your B-Complex

Month seven of the cut, Jake walked into a session and asked if the numbness in his left forefoot was something he should worry about. He was down 94 pounds at that point on his way to 112 total (308 to 196, 9.5 months start to finish), running a day-shift hospital security supervisor role that had him on concrete floors for ten-hour blocks. The easy read was compression from new shoes on a frame that had shed a third of its mass. The harder read was that aggressive caloric restriction plus high-dose metformin in his stack plus a decade of pre-diet glucose excursions had quietly drained his tissue thiamine stores, and the B-complex he had been pulling off the shelf was not replacing them.

We ran erythrocyte transketolase activity. It came back in the lower quartile. We pulled the generic B-complex, dropped in benfotiamine at 300mg twice daily with fat-containing meals, and held everything else constant. Paresthesia resolved inside nineteen days.

That is not a supplement anecdote. That is a pharmacokinetics problem almost every fitness program misses.

The Absorption Ceiling Nobody Prints on the Label

Thiamine hydrochloride is water-soluble and enters enterocytes through two saturable transporters, THTR1 (SLC19A2) and THTR2 (SLC19A3). Above roughly 5mg per oral dose, fractional absorption collapses from about 50 percent to under 10 percent. The 100mg thiamine HCl stamped on your B-complex is marketing. Your duodenum processes perhaps 8 to 12mg of it and excretes the rest.

Benfotiamine, S-benzoylthiamine-O-monophosphate, is a lipid-soluble thiamine analogue. It crosses intestinal membranes via passive diffusion, bypasses the transporter bottleneck, and once inside tissue is cleaved by ectoalkaline phosphatases into free thiamine and then phosphorylated to thiamine pyrophosphate (TPP), the active cofactor. The 1998 Arzneimittel-Forschung pharmacokinetic comparison (Loew) put peak plasma thiamine from benfotiamine at roughly 5-fold higher than equimolar thiamine HCl, and erythrocyte TPP at approximately 120 percent higher over 24 hours.

For anyone running real metabolic stress (shift rotation, GLP-1 or GLP-3 protocols, heavy training volume, metformin use, CIDP-adjacent peripheral neuropathy, pre-diabetic glycation pressure) the delta is not academic.

What BENDIP Actually Showed

The BENDIP trial (Stracke et al., Experimental and Clinical Endocrinology and Diabetes, 2008) is the paper worth knowing cold. 181 patients with symptomatic diabetic polyneuropathy, six-week randomized double-blind placebo-controlled design, three arms: placebo, benfotiamine 300mg daily, benfotiamine 600mg daily.

The 600mg arm showed a 35.3 percent reduction in Neuropathy Symptom Score versus a 21.3 percent reduction in the placebo arm (p = 0.033), with the strongest effect on pain subscore. The 300mg arm tracked between the two. No serious adverse events in either dose group. The dose-response was real and linear within the range tested.

Stracke's earlier 2001 pilot (Experimental and Clinical Endocrinology and Diabetes) on 40 patients over 12 weeks had already shown nerve conduction velocity improvement in the peroneal nerve of roughly 1.2 m/s versus baseline, a mechanistic signal consistent with the symptom data.

The mechanism trail runs through Michael Brownlee's work at Einstein. Thiamine-dependent transketolase redirects glyceraldehyde-3-phosphate and fructose-6-phosphate out of the four hyperglycemia-driven damage pathways (polyol, hexosamine, PKC, AGE formation) into the pentose phosphate shunt. Hammes et al. (Nature Medicine, 2003) showed benfotiamine blocked three of those four pathways in diabetic rat retina and prevented experimental retinopathy. You are not just quieting nerve pain. You are rerouting the substrate flux that drives the glycation damage in the first place.

Who Actually Needs It

Not everyone. The honest answer is that a non-diabetic, non-shift-working, non-medicated lifter eating 3,200 kcal of whole food probably clears thiamine requirements on pork, legumes, and fortified grain. Benfotiamine for that person is a rounding error.

The populations where the 5-fold tissue delta actually matters:

• Rotating or permanent night shift workers. Circadian disruption depresses transketolase activity independent of intake (Reinke, Chronobiology International, 2011, roughly 18 percent lower TKA in night-shift nurses versus matched day workers).
• Anyone on metformin longer than 12 months. The drug impairs thiamine transport through THTR2 downregulation.
• Aggressive caloric deficits, particularly GLP-1 or GLP-3 protocols where food volume drops 40 to 60 percent. Retatrutide users should pay attention here.
• CIDP and CIDP-adjacent patients where high-dose thiamine has shown benefit but oral HCl cannot hit tissue targets.
• Anyone running HbA1c above 5.7 regardless of formal diabetes diagnosis.

The Protocol Worth Running

Dose: 300mg twice daily, total 600mg. Split matters less than dose, but splitting smooths plasma curve and tracks the BENDIP arm.

Timing: with meals containing at least 10 to 15g of fat. Benfotiamine is fat-soluble. Dry-stomach dosing cuts absorption by roughly a third in the Loew data.

Stack: pair with the rest of the methylated B-complex (methylfolate, methylcobalamin, P5P for B6) because thiamine metabolism depends on the others. Add magnesium glycinate at 300 to 400mg, because TPP is a Mg-dependent cofactor and most of the population is subclinically deficient. D3 at 5,000 IU with K2 MK-7 at 100mcg covers the adjacent cofactor gap.

Duration: 6 to 12 weeks minimum before you assess. BENDIP measured at six weeks. Real-world nerve response often extends to 12.

Monitoring: erythrocyte transketolase activity or whole-blood thiamine at baseline and 12 weeks if you can get the labs. If you cannot, track symptom VAS score weekly on a 0 to 10 scale. Response below three weeks is uncommon. No response by week 10 means you are looking at a different etiology.

Contraindications are minimal. No documented interactions at physiologic doses. Benfotiamine does not accumulate the way fat-soluble vitamins do, because the benzoyl group is cleaved enzymatically before tissue storage and excess free thiamine still clears renally.

The core point: a B-complex that lists 100mg thiamine HCl is selling you a number that your gut cannot process. If the clinical target is actual tissue TPP, benfotiamine at 600mg daily is the only oral form with trial data showing it hits. Everything else is label theater.